Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?

Biomark Med. 2013 Dec;7(6):823-5. doi: 10.2217/bmm.13.127.
No abstract available

Publication types

  • Introductory Journal Article
  • Research Support, N.I.H., Intramural

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Biomarkers / urine*
  • Humans
  • Male
  • Prognosis
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / metabolism

Substances

  • Antineoplastic Agents
  • Biomarkers